Serum interleukin-10 levels and adverse events in patients with acute coronary syndrome: A systematic review and meta-analysis

Chinese Medical Journal

Volumn 127, Issue 1, 2014, Pages 150-156

  Liu, Jun ^a   Jia, Yan Jun ^a   Li, Xiao Lin ^a   Xu, Rui Xia ^a   Zhu, Cheng Gang ^a   Guo, Yuanlin ^a   Wu, Na Qiong ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Cardiovascular event; Interleukins; Meta analysis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE MB; INTERLEUKIN 10; TROPONIN; TUMOR NECROSIS FACTOR;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HOMEOSTASIS; HUMAN; INFLAMMATION; INFORMATION PROCESSING; META ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; RISK FACTOR; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW;

ACUTE CORONARY SYNDROME; HUMANS; INTERLEUKIN-10;

EID: 84891672468     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131202     Document Type: Article

References (34)

1. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-e24.
2. Pinderski-Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Judith A, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-2853.
3. Li JJ, Li YS, Fang CH, Hui RT, Yang YJ, Cheng JL, et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin-10 in patients with unstable angina. Heart 2006; 92: 529-530.
4. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on anti-inflammatory cytokine interleukin-10 in patients with unstable angina. Clin Chem 2005; 51: 1735-1738.
5. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-749.
6. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM, et al. CAPTURE Study Investigators. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005; 45: 229-237.
7. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Soluble CD40 ligand: interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res 2007; 121: 293-299.
8. Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R, et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med 2011; 124: 724-730.
9. Welsh P, Murray HM, Ford I, Trompet S, de Craen AJ, Wouter-Jukema J, et al. PROSPER Study Group. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol 2011; 31: 2338-2344.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Clarke M, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
11. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427-437.
12. Inoue T, Komoda H, Nonaka M, Kamedaa M, Uchida T, Nodea K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008; 124: 319-325.
13. Kwaijtaal M, van Diest R, Bär FW, van der Ven AJ, Bruggemana CA, de Baets MH, et al. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention. Atherosclerosis 2005; 182: 341-348.
14. Lakoski SG, Liu YM, Bridget-Brosnihan K, Herrington DM. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis 2008; 197: 443-447.
15. Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Matin JL, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002; 144: 811-817.
16. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-2114.
17. Chalikias GK, Tziakas DN, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol 2007; 117: 333-339.
18. Mälarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart 2008; 94: 724-729.
19. Seljeflot I, Hurlen M, Solheim S, Arnesen H. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost 2004; 2: 350-352.
20. Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, Gullestad L, et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol 2005; 46: 2018-2021.
21. Yip HK, Youssef AA, Chang LT, Yang CH, Sheu JJ, Chua S, et al. Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Circ J 2007; 71: 1086-1091.
22. Chang LT, Yuen CM, Sun CK, Wu CJ, Sheu JJ, Chua S, et al. Role of stromal cell-derived factor-1(alpha), level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2009; 73: 1097-1104.
23. Kaski JC, Fernández-Bergés DJ, Consuegra-Sánchez L, Fernández JMC, García-Moll X, Mostaza JM, et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome-results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis 2010; 212: 636-643.
24. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation 2005; 111: 863-870.
25. Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 2005; 182: 135-143.
26. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 2005; 352: 1685-1695.
27. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 2010; 7: e1000286.
28. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.
29. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-344.
30. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, Groux H, et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 1474-1478.
31. Fiehn C, Paleolog EM, Feldmann M. Selective enhancement of endothelial cell VCAM-1 expression by interleukin-10 in the presence of activated leucocytes. Immunology 1997; 91: 565-571.
32. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43:1790-1800.
33. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-794.
34. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJH, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165: 2783-2789.